CytomX Therapeutics Q3 EPS $(0.09) Beats $(0.10) Estimate, Sales $1.688M Miss $4.925M Estimate
Benzinga Newsdesk 20 hours ago
NewsEarningsEarnings BeatsEarnings Misses
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.10) by 0 percent. This is unchanged from the same period last year. The company reported
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.10) by 0 percent. This is unchanged from the same period last year. The company reported quarterly sales of $1.688 million which missed the analyst consensus estimate of $4.925 million by 65.73 percent. This is a 71.69 percent decrease over sales of $5.963 million the same period last year.